|Systematic (IUPAC) name|
|Mol. mass||381.421 g/mol|
CECXG (3'-ethyl-LY-341,495) is a research drug which acts as a potent and selective antagonist for the group II metabotropic glutamate receptors (mGluR2/3), with reasonable selectivity for mGluR3. While it is some five times less potent than LY-341,495 at mGluR3, it has 38x higher affinity for mGluR3 over mGluR2, making it one of the few ligands available that is able to distinguish between these two closely related receptor subtypes.
- Collado I, Ezquerra J, Mazón A, Pedregal C, Yruretagoyena B, Kingston AE, Tomlinson R, Wright RA, Johnson BG, Schoepp DD (October 1998). "2,3'-disubstituted-2-(2'-carboxycyclopropyl)glycines as potent and selective antagonists of metabotropic glutamate receptors". Bioorganic & Medicinal Chemistry Letters 8 (20): 2849–54.
- Jan Egebjerg, Povl Krogsgaard-Larsen, Arne Schousboe. Glutamate and gaba receptors and transporters: structure, function and pharmacology. pp 171-173. Taylor & Francis, 2002. ISBN 0-7484-0881-9
- Sørensen, U. (2003). "Synthesis and Structure–Activity Relationship Studies of Novel 2-Diarylethyl Substituted (2-Carboxycycloprop-1-yl)glycines as High-Affinity Group II Metabotropic Glutamate Receptor Ligands". Bioorganic & Medicinal Chemistry 11: 197–205.
- Ure, J.; Baudry, M.; Perassolo, M. (2006). "Metabotropic glutamate receptors and epilepsy". Journal of the neurological sciences 247 (1): 1–9.